RBQM innovator CluePoints has announced that Richard Young has been appointed as its new Chief Strategy Officer. With 30 years of experience in clinical data management, Richard is an expert in his field.
Richard has previous experience at Medidata, Cmed Group and PAREXEL International. His most recent role was Vice President, Strategy, Clinical Data, at Veeva Systems. Richard has also acted as the Conference Committee Leader for the SCDM Annual Conference for the past three years, and is currently leading their innovations committee. His wealth of experience will ensure CluePoints’ continued growth and development as the leading provider of integrated data review software.
Andy Cooper, CEO at CluePoints, commented: “At CluePoints we are committed to innovation and turning data into positive outcomes in clinical trials. Richard has extensive experience of clinical data management and data review, and is a well-regarded expert in his field. His thought leadership is exemplified through his successful podcast series and work on industry forums. Richard sees the journey we are on, our mission to provide the best-in-class integrated data interrogation and risk management platform, and wants to support us on that continued journey.”
Also Read: SYSPRO Wins 2024 SaaS Awards for Best ERP / MRP
Richard Young reinforced the opportunities on offer: “Our industry is living through a digital inflection point, with technology offering us the opportunity to fuel and deliver step changes into global healthcare. Having successfully delivered Veeva Clinical Data, I want to contribute to the next step in realizing the potential for data to reshape and redefine research and development. I believe CluePoints is the perfect place to do that.”
Andy Cooper, CEO at CluePoints, added: “Richard will drive the strategy for our product portfolio ensuring the value of our products is aligned with our customers’ needs and we are planning, not just for what is needed this year, but what is needed in five years’ time. He will ensure we remain a leader in RBQM while also establishing ourselves as the market leader for integrated AI-driven SaaS solutions to analyze and interrogate clinical trial data.”
SOURCE: PRNewswire
